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ABSTRACT Isavuconazole (ISZ) is a newly available broad-spectrum triazole agent
recently approved for the treatment of both invasive aspergillosis and mucormyco-
sis. The aim of this study was to develop a simple and reliable method for therapeu-
tic drug monitoring (TDM) of ISZ in human plasma samples. The method involves
using a kit from ChromSystems intended for TDM of itraconazole (ITZ), posaconazole
(PSZ), and voriconazole (VRZ) in serum/plasma for sample preparation and high-
performance liquid chromatography, using ﬂuorescence detection with emission and
excitation wavelengths set to 261 and 366 nm, respectively. The assay was linear
over the ISZ concentration range of 0.2 to 20.0 mg/liter, using a 0.1-ml sample vol-
ume. The inter- and intraday coefﬁcients of variation were all below 3.7%, whereas
the accuracies ranged from 95.0 to 106.2% and the mean extraction recovery was
91.9%. In addition, the method worked well using four different Vacutainer types,
with six different healthy volunteers and under a number of relevant storage condi-
tions. Finally, the ISZ detection could be seamlessly implemented in the TDM kit for
VRZ, PSZ, and ITZ, enabling simultaneous detection of all four triazoles. This method
proved to be simple, accurate, precise, and well suited for routine analysis work. It
has been implemented in our laboratory for the simultaneous quantitative analysis
of ISZ, VRZ, PSZ, and ITZ for TDM and pharmacokinetic research.
IMPORTANCE Isavuconazole is a new broad-spectrum triazole agent recently ap-
proved for the treatment of both invasive aspergillosis and mucormycosis. Currently,
there is no consensus regarding the potential need for TDM of isavuconazole, and
no therapeutic window has been deﬁned. However, at the ECIL-6 meeting in 2015, it
was advised that TDM is indicated in a number of different settings. In this study,
we describe a rapid and validated isocratic HPLC method for ﬂuorescence-based de-
tection and quantiﬁcation of isavuconazole in human plasma/serum samples. The
method is simple and efﬁcient with good accuracy and precision and importantly
only requires a small volume of patient plasma/serum. Furthermore, this method is
highly sensitive and selective and can be detected simultaneously with the three
other triazoles, itraconazole, voriconazole, and posaconazole, without the need for
expensive mass spectrometry equipment.
KEYWORDS HPLC, isavuzonazole, TDM, therapeutic drug monitoring, ﬂuorescence
detection, triazoles
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Therapeutic drug monitoring (TDM) is indicated for serious infections when thetherapeutic window is narrow or bioavailability is unreliable. In mycology, this is the
case for ﬂucytosine, itraconazole (ITZ), voriconazole (VRZ), and posaconazole (PSZ).
Isavuconazole (ISZ) (4-{2-[(1R,2R)-(2,5-diﬂuorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-
triazol-1-yl)-propyl]-1,3-thiazol-4-yl}benzonitrile) is a novel triazole with a broad-spectrum
in vitro activity against a range of clinically relevant yeasts and molds (Fig. 1A) (1–4). It
is available as a prodrug (isavuconazonium sulfate) which is rapidly and completely
converted to the active form by plasma esterases. It is licensed for primary therapy of
invasive aspergillosis in adults by both the U.S. Food and Drug Administration (FDA)
and the European Medicines Agency (EMA) and for primary (FDA) and second-line
(EMA) therapy for invasive mucormycosis. Standard dosing is 200 mg three times daily
the ﬁrst 2 days (a total of 6 times), then 200 mg daily (intravenous, parenteral, or oral
therapy), with no licensed dose escalation option (5, 6). The bioavailability is 98% and
is not affected by food intake or gastric pH. Isavuconazole is extensively distributed,
with a mean steady-state volume of distribution of approximately 450 liters. It is highly
bound (99%) to human plasma proteins, predominantly to albumin. In vitro/in vivo
studies indicate that the cytochrome P450 enzymes CYP3A4, CYP3A5, and subse-
quently UDP glucuronosyltransferases (UGT) are involved in the metabolism of ISZ (5).
In a randomized, controlled, noninferiority phase III clinical trial comparing ISZ to
VRZ for primary treatment of invasive mold disease caused by Aspergillus spp. and other
ﬁlamentous fungi, the steady-state ISZ trough plasma concentration ranged from 0.81
to 9.95 mg/liter, with a mean of 3.4 mg/liter (standard deviation [SD], 1.8 mg/liter) (7).
The EUCAST epidemiological cutoff value for Aspergillus fumigatus is 2 mg/liter. How-
ever, the ISZ MICs for wild-type A. fumigatus isolates and for A. fumigatus isolates
harboring CYP51A azole target gene mutations overlap. Therefore, a MIC of 2 mg/liter
may represent a wild-type isolate, or a mutant isolate with reduced susceptibility.
Monte Carlo simulations using the data from the clinical trial suggested that for
patients with infections due to isolates with an MIC of 2 mg/liter, approx. 25% will not
achieve an area under the concentration-time curve (AUC)/MIC ratio of 33, which is
needed for 90% efﬁcacy (8).
Currently, there is no consensus regarding the potential need for TDM for ISZ, and
no therapeutic window has been deﬁned. At the ECIL-6 meeting in 2015, it was advised
that TDM is indicated in the setting of breakthrough or infections unresponsive to
treatment, treatment of pathogens with reduced susceptibility, or in the setting of drug
interactions (CIII recommendation), but it was also clearly highlighted that additional
data are needed (9). Currently, there are only a few published validated detection
methods for TDM on plasma/serum samples that include ISZ. One publication involved
ultraperformance liquid chromatography (UPLC) with UV detection (10), while two
other publications included detection by tandem mass spectrometry (11, 12).
We routinely perform simultaneous TDM of ITZ, VRZ, or PSZ. For this purpose, we
use a ﬂuorescence-based HPLC TDM kit commercially available from ChromSystems.
This method is quick, reliable, and highly selective. Also, importantly, this method only
relies on an isocratic mobile phase using a simple HPLC system equipped with a
ﬂuorescence detector. To our knowledge, there is no published description of a
validated method for ﬂuorescence-based detection of ISZ in human plasma or serum.
Since ISZ is structurally related to the three other triazoles, we decided to determine if
the same ﬂuorescence-based HPLC TDM kit could also be used for TDM of this new
antifungal.
RESULTS AND DISCUSSION
Isavuconazole structure and chromatographic characteristics. Because of its
ﬂuorescent properties, ISZ can be detected using a ﬂuorescence detector with emission
and excitation wavelengths set to 261 and 366 nm, respectively. To perform the plasma
sample preparation, we used the reagents included in the HPLC-based TDM kit from
ChromSystems that is intended for simultaneous detection of ITZ, PSZ, and VRZ. This kit
also includes an acetonitrile-based mobile phase for the HPLC. Figure 1B shows an
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analytical chromatogram for blank ﬁltered pooled human plasma, a quality control (QC)
sample including an internal standard, and a sample spiked with ISZ at 1.0 mg/liter. All
three samples were run for 13 min, as suggested in the ChromSystems manual. The
retention time of ISZ was approximately 12.1 min, and the peak was well eluted by the
end of the 13-min run time cycle.
Calibration curve. To create a calibration curve, human plasma samples were
spiked with ISZ at seven different concentrations ranging from 0.2 to 20.0 mg/liter and
applied to the HPLC column (Fig. 2A). Plotting the integrated areas as a function of
concentration revealed that the assay was linear within the range and resulted in a
correlation coefﬁcient (r2  0.99) with regression intercepts not statistically different
from zero (Fig. 2B). At ISZ concentrations higher than 20 mg/liter, the ﬂuorescence
detector quickly reached the saturation level, and hence this concentration was set as
the upper limit of quantiﬁcation.
Lower limit of quantiﬁcation. The lower limit of quantiﬁcation (LLOQ) was deter-
mined to be 0.2 mg/liter for ISZ in ﬁltered pooled human plasma, as lower concentra-
tions resulted in unacceptable accuracy and precision values.
Accuracy, precision, and recovery. The method showed good accuracy and
precision in the ﬁltered pooled human plasma samples. Table 1 summarizes the intra-
and interday accuracy and precision values for ISZ in plasma samples. The average
intraday and interday values for LLOQ and the three QC samples were 99.4% and
101.1%, respectively. Similarly, average intraday and interday precision coefﬁcients of
variation (CVs) were 2.30% and 2.74%, respectively. Hence, the sensitivity of the method
was satisfactory and sufﬁciently covered the therapeutic range of ISZ in plasma, which
can be expected to lie approximately between 0.5 and 10.0 mg/liter (7). Finally, Table 1
also shows that the extraction mean recoveries of ISZ in the spiked plasma samples
ranged from 84.5% to 101.8%, with an average of 91.9%. No detectable carryover was
observed in a number of runs where a blank sample was injected immediately after
running several high-concentration quality control (HQC) samples on the HPLC column.
Matrix effect and selectivity. Intraday accuracy and precision values on blood
collected from the same person in four different BD Vacutainer tubes (including a tube
for serum separation) revealed no signiﬁcant matrix effects (Table 2). Furthermore, the
selectivity of the method was evaluated by analyzing serum from six volunteers; in
FIG 1 Detection of ISZ. (A) Chemical structure of ISZ. The chemical formula is C22H17F2N5OS, with a
molecular mass of 437.47 g/mol. (B) Chromatogram on ﬁltered pooled human plasma spiked with ISZ
and prepared according to the instruction manual for the TDM kit. For improved visualization the red and
blue lines were transformed by adding 1.5 and 3.0 million counts, respectively, to the measured values
at all time points. A clear symmetric peak for ISZ appears in the chromatogram, with a retention time
around 12.1 min. I.S., internal standard.
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these samples no interference by endogenous components was noted (see Fig. S1 in
the supplemental material). In particular, we saw no interference around the ISZ
retention time and intraday accuracy, and precision values on low-concentration
quality control (LQC) and HQC serum samples from the volunteers were also well within
the limits of the EMA guidelines (Table S1). Also, according to the instruction manual
of the TDM kit, several known compounds can cause additional peaks in the chromato-
gram. However, these compounds primarily elute with retention times between 3.2 and
FIG 2 Calibration of ISZ. (A) Chromatogram of prepared ISZ-spiked human plasma samples at different
concentrations, from 0.2 to 20 mg/liter. I.S., internal standard. (B) A calibration curve based on the
integrated area of the ISZ peaks, averaged from two repetitions, shows that the concentration range is
linear. The r2 value is the result of a linear ﬁt, calculated by using Prism 6.
TABLE 1 Intraday precision, accuracy, and average recovery and interday precision and










(mean %  SD)
Intraday
LLOQ (0.2) 0.190  0.004 95.0 2.07 84.5  3.3
LQC (0.3) 0.311  0.003 103.8 0.86 88.5  1.9
MQC (8.0) 7.908  0.273 98.8 3.45 92.6  2.6
HQC (20.0) 20.008  0.558 100.0 2.79 101.8  4.4
All samples 99.4  3.6 2.30  1.1 91.9  7.4
Interday
LLOQ (0.1) 0.212  0.003 106.2 1.60
LQC (0.3) 0.296  0.007 98.6 2.42
MQC (8.0) 8.004  0.261 100.0 3.26
HQC (20.0) 19.910  0.734 99.5 3.69
All 101.1  3.4 2.74  0.9
aIntraday precision, accuracy, and average recovery were measured within a single day (n  5), and interday
precision and accuracy were measured on four separate days (n  20). Five individually prepared samples
were evaluated at each concentration level.
bAccuracy is the percentage of the nominal value.
cPrecision is expressed as the percentage of the RSD of each calculated concentration.
dRecovery is the percent extraction mean recovery.
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7.8 min. In addition, the instruction manual reports a broad range of compounds which
have been tested and shown to not interfere with this kit’s performance.
Stability. The inﬂuence of various possible storage conditions between sample
collection and analysis were examined using two concentrations of ISZ (LQC and HQC).
Working solutions of ISZ dissolved in ﬁltered pooled human plasma showed no
perceptible degradation between solutions kept at room temperature for 24 h versus
7 days, at 20°C for 48 h versus 60 days, or in freshly prepared samples (Table 3). Also,
three freeze-thaw cycles of working solutions indicated that ISZ was stable under these
conditions. Finally, we found that working solutions of ISZ mixed with the internal
standard and stored for 24 h at room temperature, as well as prepared samples stored
for 24 h in the autosampler at room temperature, were stable.
Simultaneous detection of ISZ, VRZ, PSZ, and ITZ. As ISZ can be detected using
the TDM kit, we decided to attempt simultaneous detection of all four mold-active
triazoles. Initially, we added 1 ml of human plasma containing 1.2 mg/liter ISZ to a vial
of the plasma calibration standard (PCS) containing lyophilized VRZ, PSZ, ITZ, OH-ITZ,
and the internal standard. This was then used for sample preparation, applied to the
HPLC column, and compared with a PCS without ISZ (Fig. 3A). The chromatogram
revealed that ISZ is generally well separated from the other analytes and that adding
ISZ did not interfere with any of the other integrated peak areas. For simultaneous
creation of calibration standards, we also added various concentrations of ISZ to the
three plasma control level vials (PCL I to III) as described above (Fig. 3B). Again, ISZ was
well separated from the other analytes, although at higher concentrations of the
analytes (PCL III) the peaks of ITZ and ISZ slightly overlapped. However, from the three
chromatograms, reliable linear calibration curves of all the analytes could be generated
(data not shown).
Conclusions. This is the ﬁrst report of a rapid and validated isocratic HPLC method
that describes the ﬂuorescence-based detection and quantiﬁcation of ISZ in human
plasma samples. We showed that ISZ is linear within a therapeutic concentration range
of 0.2 to 20.0 mg/liter. The ISZ retention time of approximately 12.1 min allows the run
time to remain within the recommended 13 min according to the instruction manual
for the kit. The method is simple and efﬁcient, with good accuracy and precision, and
importantly, it only requires a small volume of human plasma/serum. Fluorescence-
based detection is generally more sensitive and selective than UV absorption and offers
high reliability in the identiﬁcation and determination of compounds of interest while
TABLE 2 Matrix effect of ISZ
Vacutainer tube and sample
concna (mg/liter)
Found concn






LQC (0.3) 0.307  0.008 102.3 2.50
HQC (20.0) 19.599  0.391 98.0 2.00
K2E
LQC (0.3) 0.309  0.012 103.0 4.04
HQC (20.0) 19.901  0.368 99.5 1.85
LH
LQC (0.3) 0.299  0.006 99.5 2.04
HQC (20.0) 20.271  0.141 101.4 0.70
Serum
LQC (0.3) 0.316  0.020 105.3 6.18
HQC (20.0) 19.238  0.636 96.2 3.31
aIntraday precision and accuracy values were determined for the LQC and HQC in human blood samples
collected in four different BD Vacutainer tubes. There were ﬁve individually prepared samples at each
concentration level. CSC, coagulation sodium citrate (3.2%); K2E, EDTA; LH, lithium heparin; serum, clot
activator for serum separation.
bAccuracy is the percentage of the nominal value.
cPrecision is expressed as the percentage of the RSD of each calculated concentration.
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still avoiding the requirement for expensive mass spectrometry equipment. Hence, this
method is suitable for the estimation of ISZ at different therapeutic dose levels for
pharmacokinetic studies as well as TDM in adults and children. However, during the
validation of this method, we occasionally experienced that the standard deviation of
the internal standard measurements in a sequence of samples were higher than the ISZ
measurements, and at times this resulted in elevated accuracy and precision values.
This phenomenon is also seen when using the kit purely for detection of ITZ, PSZ, or
VRZ, but it only rarely calls for repetition of the experiment. It is possible that using a
different kind of internal standard could optimize the method. The extraction mean
recoveries of ISZ-spiked plasma samples (LLOQ and the three QCs) compared to direct
injections of ISZ dissolved in the mobile phase were all acceptable. However, the
recovery values showed a trend toward lower recovery at lower ISZ concentrations.
Possibly, the ISZ-binding capability of the plasma proteins causes the removal of small
amounts of ISZ when the protein is precipitated during sample preparation.
Additionally, a major advantage of this methodology is that the kit allows for
simultaneous quantiﬁcation of ISZ together with the three other triazoles. This is
convenient and clinically advantageous. First, as neither column nor mobile phase
needs to be changed depending on the speciﬁc azole concentration requested, a short
turnover time is allowed. Second, a relevant result is obtained without delay even in the
scenario where an incorrect request has been placed, which in our experience is not a
rare event (e.g., due to change of medication but not sampling order). When larger
concentrations of ITZ and ISZ are both present in the sample, the two peaks are not
separated completely from each other. However, this is a rare phenomenon since the
two compounds are not given in combination and given the fact that it is recom-
mended to measure drug levels at steady state (day 4 to 7), meaning that in the
scenario of a switch from ITZ to ISZ the level of ITZ will inevitably be low due to timing
TABLE 3 Stability of ISZ in plasmaa
Storage condition and sample
concn (mg/liter)
Found concn





24 h at 20°C
LQC (0.3) 0.300  0.003 100.1 0.833
HQC (20.0) 19.603  0.142 98.0 0.727
7 days at 20°C
LQC (0.3) 0.292  0.005 97.2 1.652
HQC (20.0) 19.373  0.420 96.9 2.170
Freeze (20°C) for 48 h
LQC (0.3) 0.312  0.008 104.0 2.606
HQC (20.0) 20.265  0.575 101.3 2.840
Freeze (20°C) for 60 days
LQC (0.3) 0.319  0.040 106.4 12.545
HQC (20.0) 22.119  0.941 110.6 4.255
Three freeze-thaw cycles
LQC (0.3) 0.308  0.014 102.7 4.611
HQC (20.0) 21.526  0.500 107.6 2.321
Sample  IS for 24 h at 20°C
LQC (0.3) 0.298  0.009 99.2 3.082
HQC (20.0) 21.654  0.275 108.3 1.272
In autosampler for 24 h at 20°C
LQC (0.3) 0.291  0.005 97.0 1.598
HQC (20.0) 19.172  0.542 95.9 2.825
aIntraday precision and accuracy values were determined for the LQC and HQC in ﬁltered pooled human
plasma samples after storage under various conditions. Five individually prepared samples were used for
each concentration level and storage condition. IS, internal standard.
bAccuracy is the percentage of the nominal value.
cPrecision is expressed as the percentage of the RSD of each calculated concentration.
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and often poor availability when it is indicated to measure ISZ. In the event of switching
from ISZ to ITZ, it cannot be excluded that signiﬁcant amounts might be present at the
time of clinically indicated ITZ TDM. In such cases, we advise to use the heights of the
two peaks when the areas overlap. We see no difference in accuracy and precision
when measuring peak heights compared to measuring peak areas.
MATERIALS AND METHODS
Chemicals and standards. Isavuconazole was kindly supplied by Basilea Pharmaceutica Ltd. (Basel,
Switzerland). The standard stock solution of ISZ was prepared at a concentration of 5.000 mg/liter in
dimethyl sulfoxide (99.7% pure; Chromasolv Plus) and diluted to a 160-mg/liter working solution in
ﬁltered pooled human plasma (BioWest) or plasma from healthy volunteers. The stock solution and
working solution were stored at 20°C. The chemicals for sample preparation and HPLC were obtained
from the itraconazole/posaconazole/voriconazole reagent kit for TDM on plasma/serum samples avail-
able in Europe (ChromSystems Instruments and Chemicals GmbH, Germany), which also included a
plasma calibration standard (PCS), plasma control level I, II, and III (PCL I to III), and also the HPLC column
provided for the kit. The PCS is a control designed for calibrating the measurement method and contains
predetermined concentrations of ITZ (0.83 mg/liter), OH-ITZ (1.1 mg/liter), VRZ (2.95 mg/liter), PSZ
(2.38 mg/liter), and internal standard. A PCS including ISZ was prepared by diluting the ISZ working
solution to 1.2 mg/liter in ﬁltered pooled human plasma before using 1 ml of this solution to reconstitute
the PCS according to the instructions of the manufacturer. PCL I, II, and III are designed for calibrating
the measurement method and contain the following predetermined concentrations of ITZ (0.28, 0.56,
and 1.37 mg/liter), OH-ITZ (0.42, 0.83, and 2.3 mg/liter), VRZ (1.01, 2.46, and 4.72 mg/liter), and PSZ (0.57,
1.19, and 4.72 mg/liter) for preparation of calibration curves. PCL I to III, including ISZ, were prepared by
diluting the working solutions to 0.48, 0.96, and 1.60 mg/liter, respectively, in ﬁltered pooled human
plasma and using 1-ml volumes of these solutions for reconstituting PCL I, II, and III. It should be noted
that according to the instructions of the manufacturer, distilled water should be used for the reconsti-
tution of PCS and PCL I to III. However, we experienced no differences in concentration values whether
we used water or human plasma (data not shown).
Instruments and chromatographic conditions. Analyses were carried out on a Vanquish UHPLC
system (Thermo Fisher Scientiﬁc) consisting of a binary pump (VH-P1-A), an autosampler with thermostat
and column compartment (VH-A10-A and VH-C10-A), and a ﬂuorescence detector (VF-D50-A). The
FIG 3 Simultaneous detection of ISZ together with ITZ, OH-ITZ, PSZ, and VRZ. (A) Chromatogram of the
PCS control before and after reconstituting the lyophilized mix of compounds with plasma containing
1.2 mg/liter of ISZ. I.S., internal standard. (B) Chromatogram of PCL I, II, and III calibrators after
reconstituting the lyophilized mix of compounds with plasma containing 0.48, 0.96, and 1.60 mg/liter of
ISZ, respectively.
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ﬂuorometric detection was conducted using emission and excitation wavelengths set at 261 and 366 nm,
respectively. The data were acquired and processed by using the Chromeleon 7.2 chromatography data
system software. Chromatographic separation was carried out on an HPLC column (supplied for the kit
by ChromSystems), with a column temperature of 25°C and an isocratic ﬂow rate of the mobile phase
(also supplied with the TDM kit from ChromSystems) of 1.2 ml/min. The run time for each sample was
13 min. All plots were prepared using Prism 6.0 (GraphPad Software, Inc.).
Sample preparation. The plasma samples were prepared according to the instruction manual for
the TDM kit. Brieﬂy, 100 l of human plasma sample was mixed with 25 l of internal standard and 25 l
of precipitation reagent I. After vortexing, 200 l of precipitation reagent II was added and the mixture
was vortexed for 30 s before centrifuging for 5 min at 15,000  g. The supernatant was then transferred
into an HPLC glass vial and placed in the sample chamber, followed by injection of 20 l of sample into
the HPLC system.
Calibration. Plasma samples spiked with ISZ were prepared in ﬁltered pooled human plasma at the
following seven concentrations: 0.2, 0.5, 1.0, 4.0, 8.0, 16.0, and 20.0 mg/liter. Each concentration was
determined as the average of two injections on the HPLC column from dilutions prepared independently
from the QC samples (see below). All calibration curves were constructed using the ratio of the observed
peak area of ISZ and the internal standard, followed by linear regression analysis (least absolute
deviation) of the data using the equation y  mx  b, where y was the peak ratio, x the concentration
of ISZ, and m and b the slope and intercept of the curve, respectively (GNU octave 4.0.3, Prism 6;
GraphPad Software, Inc.). A correlation coefﬁcient (r2) of 0.99 was desirable for each calibration curve.
LLOQ and QC samples. The LLOQ is deﬁned by the EMA guidelines for bioanalytical method
validation (13) as being at least 5 times the signal of a blank sample and the minimum amount that gives
precise measurements (accuracy and precision both within 20% of the nominal value). The low-
concentration QC (LQC) was selected as being within three times the LLOQ, the medium QC (MQC) was
between 30 and 50% of the calibration curve range, and the high QC (HQC) was at least 75% of the upper
calibration curve range.
Accuracy, precision, and recovery. Accuracy and precision were determined as deﬁned by the EMA
guidelines (13). Accuracy is the mean of the measured LLOQ, LQC, MQC, and HQC concentrations relative
to the theoretical value and is reported as a percentage of the nominal value. The overall mean precision
describes the closeness of repeated measures of an analyte expressed as the CVs and is reported as the
percent relative standard deviation (RSD) of each calculated concentration. Both precision and accuracy
values were expected to be within15% of the nominal value for all concentrations except for the LLOQ,
for which 20% was acceptable.
The intraday precision and accuracy values for plasma LLOC and QCs were calculated from ﬁve
independently spiked preparations, as described above, with each measured in duplicate on the same
day (n  5). For interday precision and accuracy, LLOC and the three QCs were prepared ﬁve times and
measured in duplicate on four separate days (n  20). Absolute recovery was determined by comparing
the mean peak areas of the ISZ and internal standard acquired after injection of the processed plasma
samples with the peaks achieved by direct injection of the identical amount of compound diluted in the
mobile phase (n  5 for each concentration level).
Effect of dilution and carryover. The effect of dilution of plasma samples was validated with a
160.0-mg/liter spiked plasma sample diluted to the HQC level in plasma and analyzed ﬁve times.
Carryover was tested by injecting two blank plasma samples immediately after ﬁve HQC ISZ injections,
followed by evaluation of ISZ disappearance.
Matrix effect and selectivity. The matrix effect was evaluated by collecting blood from the same
person in four different BD Vacutainer tubes (lithium heparin [LH], coagulation sodium citrate at 3.2%
[CSC], EDTA [K2E], and clot activator for serum separation [serum]). The selectivity of the method was
evaluated for interference of endogenous matrix components by analyzing six blank serum samples
collected in clot activator tubes from different healthy human volunteers. For these human plasma and
serum samples, intraday accuracy and precision values based on ﬁve replicates were calculated on the
LQC and HQC samples as described above. Furthermore, selectivity for ISZ was evaluated together with
a mixture of ITZ, OH-ITZ, PSZ, VRZ, and the internal standard obtained from the PCS and PCL I to III
controls from ChromSystems as described above. The manufacturer’s manual includes a long list of
immunosuppressants and antibacterial agents that do not cause interference when this TDM kit is used.
The echinocandin caspofungin has also been tested by the manufacturer and shown to not be
detectable with this kit at therapeutic levels. However, the manual mentions one example of a patient
in intensive care who was administered clindamycin, fosamprenavir, pyrimethamine, piperacillin, sulfa-
methoxazole, tazobactam, and trimethoprim, and minor interferences were noticed in the VRZ range. For
all of the compounds tested by the manufacturer, no interference was observed in the ITZ/ISZ range.
Stability. Stability of ISZ was investigated in human plasma (LQC and HQC) and evaluated after
short-term and long-term storage. The stability at room temperature was examined by preparing and
analyzing ﬁve replicates of the LQC and HQC plasma samples after 24 h and 7 days of incubation.
Similarly, stability was examined after 48 h and 60 days of incubation at 20°C as well as after 24 h at
20°C in a solution also containing the internal standard. The effects of repeated freezing and thawing on
LQC and HQC plasma samples were studied after three freeze-thaw cycles. Each freeze-thaw cycle
consisted of a minimum of 12 h frozen at 20°C followed by a complete thaw at room temperature.
Samples were prepared and analyzed after the third freeze-thaw cycle. Finally, postpreparative stability
was determined for processed LQC and HQC plasma samples left in the autosampler (20°C) for 24 h
(autosampler stability). The concentration after each storage period was considered stable if the mean
concentration of each level was within 15% of the nominal concentration.
Jørgensen et al.
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